Editorial
Declining cancer death rates — cause for optimism, caution
In many respects, this year’s report of cancer incidence and mortality from American Cancer Society, Cancer Statistics 2020, tells a familiar story.
Reflections on my 30th ASH Annual Meeting
Since having the good fortune to take on an editorial role for HemOnc Today, I have resisted the temptation to use the January editorial to provide a summary of highlights from ASH Annual Meeting and Exposition, or to enter the “reflective zone” at the turn of the year. Both seem a little predictable and formulaic.
Engaging in conversations about fertility
Among the new jargon that has found its way into our daily professional lives, “oncofertility” is one of the words I like the least.
Oncology Care Model: Progress along the learning curve
Recognizing the importance of addressing value in cancer care, I have been an interested observer, until recently, of the progress of CMS’s Oncology Care Model, or OCM.
Access to cancer clinical trials may not entirely level the playing field
There is compelling evidence that reducing variability in cancer care can improve patient outcomes and limit costs.
The unspoken truth about financial toxicity
As time goes by, I realize my clinical comfort zone is shrinking.
Patient access to new cancer treatments — an uncertain and fragile process
As Tom Brokaw eloquently stated, uncertainty is at the heart of the cancer experience for our patients.
Potholes on the road to improved cancer outcomes
“Continuous improvement is better than delayed perfection.” – Mark Twain
Timing matters — so do breaks
As oncologists, making our services as convenient and accessible as possible for our patients is a major goal and an ongoing challenge.
Difficult decisions: Slow changes for overuse of therapy at end of life
For the past few years, one component of my role as a member of the physician leadership team for oncology has been to authorize some types of inpatient treatments, especially those not typically reimbursed by insurance carriers.